乳がん腫瘍の化学療法に対する感受性に影響するエストラス・サイクルの段階
Laura Bornes1, Lennart J van Winden2, Veerle C M Geurts3
1Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Nature
|December 5, 2024
まとめ
乳がん治療への反応は,エストラス・サイクル中のネオアジュヴァント化学療法 (NAC) のタイミングに影響する. 細胞の特定の変化によって特徴づけられるディオエストラス期におけるNACの開始は,マウスとヒトにおいてより悪い結果につながります.
科学分野:
- 生殖生物学
- 腫瘍学
- 薬理学について
背景:
- ネオアジュヴァント化学療法 (NAC) に対する乳がん治療の反応は著しく異質である.
- 腫瘍のサブタイプだけでは,NACの有効性の変動を完全に説明することはできません.
- がん治療に対する生理リズムの影響は,現在も活発な研究分野である.
研究 の 目的:
- 新補助化学療法に対する乳がんの反応を調節するエストラス・サイクルの役割を調査する.
- 化学療法に対する感受性のサイクル依存的変化の潜在的メカニズムを特定する.
- NACの結果を最適化するために,エストラス・サイクルのタイミングの臨床的関連性を調べる.
主な方法:
- 乳がんの3つの異なるマウスモデルを用いて,治療開始タイミングに基づいてNACの反応を評価した.
- 閉経前の人間の患者コホートからの遡及データを分析し,エストロース・サイクル・フェーズとNACのアウトカムを相関させた.
- Epithelial-to-mesenchymal transition (EMT),腫瘍血管,免疫細胞浸透 (マクロファージ) を含む,さまざまなサイクル段階で調査されたメカニズム的要因.
主要な成果:
- ネズミのモデルでは,エストラス期に開始されたNACは,エストラス期に開始されたNACと比較して,有効性が低下したことを示した.
- 遡及的なヒトのデータは,これらの発見を裏付け,更年期前の患者でも同様のパターンを示した.
- 腫瘍血管の直径の減少とマクロファージの増加が関連しており,これらはすべて化学抵抗と関連している.
結論:
- 乳がんの化学反応感受性に影響を与える重要な赤外線リズムである.
- 神期は,新補助化学療法の有効性を低下させる生物学的条件を示します.
- マクロファージの浸透などの雌性周期に依存する要因を標的とし,治療のタイミングを最適化することで,NACの結果を改善する可能性がある.
関連する概念動画
Drugs that Stabilize Microtubules
2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
The Tumor Microenvironment
6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Hormonal Control of the Ovarian Cycle
5.2K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
5.2K


